Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

The company’s product pipeline includes various drug candidates such as emraclidine for the treatment of schizophrenia and Alzheimer’s disease psychosis; and darigabat targets epilepsy and panic ...

Also of note, AbbVie announced strong Phase III results of tavapadon in early Parkinson’s disease. Unfettered access to ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a phase 3 trial for treating early Parkinson's. The company is going to ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a phase 3 trial for treating early Parkinson's. The company is going to ...

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early ...

KOLs have expressed positive sentiments of tavapadon. Credit: Owlie Productions via Shutterstock. On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...

AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson's drug Tavapadon, which shows blockbuster potential. Key growth drivers like SKYRIZI and RINVOQ ...